Quick Answer
Aldeyra Therapeutics, Inc. reported Net Income of -$33.85 million for fiscal year 2025.
Aldeyra Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$33.85M | +39.4% |
| 2024 | -$55.85M | -48.8% |
| 2023 | -$37.54M | +39.5% |
| 2022 | -$62.02M | -7.4% |
| 2021 | -$57.78M | -53.8% |
| 2020 | -$37.55M | +38.3% |
| 2019 | -$60.83M | -56.4% |
| 2018 | -$38.89M | -74.1% |
| 2017 | -$22.34M | -19.5% |
| 2016 | -$18.70M | -54.7% |
| 2015 | -$12.09M | -133.1% |
| 2014 | -$5.19M | -139.7% |
| 2013 | $13.06M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$7.69M | +49.1% | +21.3% |
| June 30, 2025 | -$9.77M | +42.0% | +1.6% |
| March 31, 2025 | -$9.93M | -22.9% | +34.3% |
| September 30, 2024 | -$15.11M | -84.6% | +10.3% |
| June 30, 2024 | -$16.85M | -87.5% | -108.5% |
| March 31, 2024 | -$8.08M | +48.2% | +1.3% |
| September 30, 2023 | -$8.19M | +43.7% | +8.9% |
| June 30, 2023 | -$8.99M | +49.5% | +42.4% |
- Aldeyra Therapeutics, Inc. showed an increase of +39.4% in Net Income compared to the prior fiscal year.
- Over the 2013–2025 period, Aldeyra Therapeutics, Inc.’s net income has declined by 359.2% (from $13.06 million to -$33.85 million).
- The most recent figure is from Aldeyra Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: